NCT02993068Suspended
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Reason given: Accrual Limit
Brief summary (registry, in English)
This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.
- Status (registry)
- Suspended
- Study type
- Interventional
- Enrollment
- 5200 (estimated)
- First submitted
- 7 Dec 2016
- Start date
- 18 Apr 2017
- Primary completion date
- 18 Apr 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT02993068
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous genetic testing or counseling regarding cancer risk
- Previous bone marrow transplant
- Previous blood transfusion (7 days prior to genetic testing)
Other illness
- Personal history of ovarian cancer
- Active hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)
Other
- Unable to read, speak, and understand English
- Unable to provide informed consent
- Unwilling to complete baseline and follow-up questionnaires
- Unable to access the internet
Who the study is looking for
- Age 30 or older. Note: Participants must meet each of Criteria 1-4.
- Have access to a healthcare provider and be willing to share genetic results with that provider
- Have at least one ovary
- Have a valid United States mailing address for receipt of saliva kit
- Participants must meet any one of the following 6 criteria:
- Diagnosed with breast cancer at age 45 or younger
- Diagnosed with triple negative (negative for estrogen receptor, progesterone receptor and not human epidermal growth factor receptor 2 [Her2] amplified) breast cancer at 60 or younger
- Have one blood relative with a mutation in BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, or PMS2
- Have one relative with ovarian cancer
- Have at least 2 relatives with breast cancer on the same side of the family, one of which is =< 50 years of age
- Have one male relative with breast cancer
Age in the registry: 30 years to - · Sex: Female · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center | Houston | United States | Unknown status |
| University of Washington Medical Center | Seattle | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.